UTHR Latest Press Releases

-- November 9, 2026 --

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences Business Wire 7:00 AM

-- November 4, 2026 --

United Therapeutics Announces Buydown of Ralinepag Royalty Business Wire 7:00 AM

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results Business Wire 6:30 AM

-- October 28, 2026 --

United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension Business Wire 7:00 AM

-- October 22, 2026 --

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization Business Wire 7:00 AM

-- October 21, 2026 --

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 Business Wire 7:00 AM

-- October 20, 2026 --

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility Business Wire 7:00 AM

-- October 19, 2026 --

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD Business Wire 7:00 AM

-- October 13, 2026 --

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Globe Newswire 5:44 PM

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting Business Wire 7:00 AM

-- October 1, 2026 --

HLS Therapeutics Announces Board of Directors Changes PRNewswire 7:00 AM

-- September 30, 2026 --

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia Business Wire 7:09 PM

-- September 8, 2026 --

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization Business Wire 7:00 AM

-- September 2, 2026 --

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso to Treat Idiopathic Pulmonary Fibrosis Business Wire 7:00 AM

-- September 1, 2026 --

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences Business Wire 7:00 AM

-- August 28, 2026 --

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026 Business Wire 7:00 AM

-- August 24, 2026 --

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension Business Wire 7:00 AM

-- August 17, 2026 --

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis Business Wire 7:00 AM

-- August 5, 2026 --

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results Business Wire 6:30 AM

-- July 29, 2026 --

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet Business Wire 6:30 AM

-- July 23, 2026 --

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors Business Wire 6:30 AM

-- July 22, 2026 --

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 Business Wire 7:00 AM

-- July 10, 2026 --

BETA Technologies and Multistate Collaborative Complete First Operational Flights of the U.S. DOT and FAA's eVTOL Integration Pilot Program Business Wire 12:35 PM

-- July 2, 2026 --

United Therapeutics Corporation Acquires Thymmune Therapeutics Business Wire 6:30 AM

-- June 29, 2026 --

United Therapeutics Corporation Announces FDA Approval of the LungFX Device for Centralized Ex Vivo Lung Perfusion Business Wire 6:30 AM

Market Data Delayed 15 Minutes